New registry to monitor PSMA therapy in prostate cancer patients
NCT ID NCT04769817
First seen May 14, 2026 · Last updated May 22, 2026 · Updated 2 times
Summary
This study is a registry that collects information on 500 men with metastatic castration-resistant prostate cancer who are treated with PSMA theranostics. The goal is to track how well the treatment lowers PSA levels and to monitor any side effects. The registry does not test a new treatment but gathers real-world data to improve future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
Conditions
Explore the condition pages connected to this study.